Aditxt Inc. (ADTX) shares tumbled nearly 17% in Tuesday's late trading session, closing at $0.0109 after hitting an intraday low of $0.0086. The micro-cap healthcare company saw unusually high trading volume of approximately 929 million shares, reflecting intense investor focus on the stock's precarious Nasdaq listing status and the uncertain outcome of its planned $150 million Ignite Proteomics spin-off.
The stock's slide comes despite a recent disclosure that HRT Financial LP acquired 4,252,767 shares at $0.016 each on June 12, a purchase that made HRT a 10% owner. However, the buying interest was insufficient to stem the selling pressure, as delisting concerns continue to dominate sentiment.
Nasdaq staff initiated delisting proceedings against Aditxt in May after the stock traded below $1 for 30 consecutive business days. The company was unable to secure an additional cure period due to its prior reverse stock split history, with a 1-for-27 reverse split having taken effect on May 18. The company also disclosed in a May 29 filing that it failed Nasdaq's stockholders' equity requirement and did not meet the exchange's market value or net income standards.
The company's primary strategic initiative, the Ignite Proteomics spin-out, was announced on June 9. Ignite, a wholly owned subsidiary focused on functional proteomics—which analyzes protein activity in tumor samples rather than just gene sequencing—is intended to become a standalone public entity pending shareholder approval, financing, and exchange listing. Jeff Busch, serving as interim CEO of both Aditxt and Ignite, described the deal as an important milestone that would provide Ignite with better access to capital.
Ignite initially targets breast cancer diagnostics but plans to expand into other tumor types. However, it enters a competitive landscape dominated by established players such as Guardant Health, which offers liquid biopsy tests, and Abbott, which recently acquired Exact Sciences' cancer testing business covering screening and precision oncology.
The broader biotech sector showed relative stability on Tuesday. The SPDR S&P Biotech ETF slipped about 0.7%, the iShares Nasdaq Biotechnology ETF declined roughly 0.4%, and the Invesco QQQ Trust, tracking large-cap Nasdaq stocks, lost about 1.9%.
Additional ownership filings revealed minimal activity from Bank of America Corp., Bank of America N.A., and BofA Securities Inc., which reported an initial filing for just 57 shares and a subsequent Form 4 showing seven shares bought and 15 sold on June 11. The firms stated they were not admitting beneficial ownership.
Aditxt faces significant risks beyond the delisting threat. In its regulatory filings, the company warned that delisting would impair liquidity, depress the share price, and hinder its ability to raise capital. The Ignite deal also remains conditional on securing shareholder approval, financing, and exchange listing, leaving the stock exposed to both deal and listing uncertainty.
